Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MedGenesis Therapeutix Inc.

This article was originally published in Start Up

Executive Summary

MedGenesis Therapeutix is developing convection-enhanced delivery, a technique that involves infusion under positive pressure of a drug to specific locations of the brain. The leading indication for its CED technology is glioblastoma.

You may also be interested in...



Start-Up Previews (07/2008)

A preview of the emerging health care companies profiled in the current, all-profiles issue of Start-Up. This month's profile groups are "Glioblastoma Start-Ups Get Specific," "Glaucoma Start-Ups Reach Critical Mass," and "ALS on the Cusp." Plus these Start-Ups Across Health Care: EarlySense, NeoChord, and Pantec Biosolutions.

Hy BioPharma Inc.

Hy BioPharma is developing hypericin phototherapeutics for cancers and autoimmune disorders. The Israeli/US start-up is also in Phase I/IIb trials for an oral formulation of hypericin for possible use in combination therapy with Temodar for the treatment of glioblastoma.

Glioblastoma Start-Ups Get Specific

For start-ups developing novel and risky medicines to treat glioblastoma, a rare, invasive form of brain cancer, the Pfizer/Avant deal was a watershed moment: It signaled the vigorous interest of a pharmaceutical behemoth in a disease where patients number in just the tens of thousands. The positive effects are likely to be felt in executive suites of biotechs developing therapeutics for this grievous disease.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC091625

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel